REPL Stock Catalyst: RP2 Data Presentation At ASCOIt enrolled 85 heavily pretreated patients with advanced solid tumors.On Sunday, the company said, RP2 monotherapy achieved an objective response rate (ORR) of 19.0% (4/21 evaluable patients).RP2 in combination with nivolumab achieved an ORR of 19.1%, with a disease control rate of 48.9%.Median duration of response (DOR) was not reached in the monotherapy group and was 22.1 months in the combination group.Tumor regression was observed in both injected and non-injected lesions, including in all 3 monotherapy responders who had non-injected lesions, demonstrating a systemic immune response beyond the site of injection.On Saturday, Replimune presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab for anti-PD-1 failed melanoma.RP1 (vusolimogene oderparepvec) plus nivolumab achieved a median overall survival (mOS) of 32.9 months. At 3 years, 47.8% of all treated patients remained alive, rising to 83.5% among responders.The ORR was 33.6%, with a median DOR of 24.8 months; 44.8% of responders maintained their response at 3 years.How Replimune (REPL) Ranks On Momentum And Market PerformanceBelow is the Benzinga Edge scorecard for Replimune Group, highlighting its strengths and weaknesses compared to the broader market: